The recently implemented measures include the divestiture of certain non-core assets and the initiation of programs designed to optimize operational efficien Agreement reinforces Scorpius' position as ...

(“Scorpius” or the “Company”), an integrated biomanufacturing company, today announced the implementation of strategic cost-saving measures expected to save over $2 million annual ...

"This collaboration reinforces Scorpius' reputation as a trusted and innovative biomanufacturing partner,” said Jeff Wolf, CEO of Scorpius. "ErythroMer™ is a groundbreaking advancement that addresses ...

DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development ...

“This collaboration reinforces Scorpius' reputation as a trusted and innovative biomanufacturing partner,” said Jeff Wolf, CEO of Scorpius.“ErythroMerTM is a groundbreaking advancement that ...

Both companies are also exploring a potential commercial-scale manufacturing agreement, reinforcing Scorpius's role as a reliable biomanufacturing partner. KaloCyte is advancing towards clinical ...

“This collaboration reinforces Scorpius’ reputation as a trusted and innovative biomanufacturing partner,” said Jeff Wolf, CEO of Scorpius. “ErythroMer™ is a ...

"This collaboration reinforces Scorpius' reputation as a trusted and innovative biomanufacturing partner," said Jeff Wolf, CEO of Scorpius. "ErythroMer is a groundbreaking advancement that ...